Navigation Links
Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
Date:10/11/2010

potential" and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, future actions by Alexza or BLS with respect to AZ-004, the FDA's review of the approvability of or other action with respect to AZ-004, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA").  

Valeant does not undertake any obligation to update or revise any forward-looking statement, except as may be required by law.Contact Information:Contact for Valeant  Laurie W. Little949-461-6002laurie.little@valeant.com(Logo: http://photos.prnewswire.com/prnh/20081125/VALEANTLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  Cephasonics, a technology-innovation leader with a game-changing ... (cQuest Ultrasound Box™-1), the first product in a new ... by Cephasonics for purchase by companies to rebrand with ... be showcasing the cQUB-1 for the first time at ... Chongqing, China from October 23 to ...
(Date:10/22/2014)... LONDON , October 22, 2014 ... Amicus Therapeutics Inc. (NASDAQ: FOLD ), Progenics ... Inc. (NASDAQ: THLD ), Idera Pharmaceuticals Inc. ... (NASDAQ: MACK). Free research on these five companies can ... Tuesday, October 21, 2014, the NASDAQ Composite ended at ...
(Date:10/22/2014)... 22, 2014   Reproductive Medicine Associates of ... the field of infertility, presents new clinical research ... The research abstract, released during the 70 th ... meeting in Honolulu, Hawaii , ... defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... NEW YORK, March 7, 2012 Reportlinker.com ... is available in its catalogue: ... and Emerging Market Entrants ... report presents analyses of major current and ...
...  HeartWare International, Inc. (NASDAQ: HTWR - ... circulatory support technologies that are revolutionizing the treatment of ... is scheduled to present at the Barclays Capital 2012 ... March 13, 2012.  The conference is being held March ...
Cached Medicine Technology:Hemostasis Diagnostics Market Leading Suppliers and Emerging Market Entrants 2HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast 2
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/22/2014)... Dennis Thompson HealthDay ... U.S. health officials on Monday officially tightened guidelines for health ... no skin exposure and use of a respirator at all ... decided to issue the tougher rules after two Dallas nurses ... in the United States, Liberian national Thomas Eric Duncan. Nina ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... of cardiovascular disease are there, researchers say , WEDNESDAY, Oct. ... for obesity show early signs of heart disease -- similar ... The study, by a team at Washington University School of ... All of the children had undergone cardiac ultrasound to check ...
... new way of ... taking daily dose of glucosamine, SAN FRANCISCO, Oct. 24 ... to help,people keep their joints hydrated and moving smoothly.* The company,launched ... Juice products: -- Original Joint Juice: ready-to-drink juice-based dietary supplement ...
... MSA (NYSE: MSA ), the,global leader in the ... health and safety, announced today that it,will broadcast a ... on Thursday, November 1, 2007 at 10:00 a.m. EDT. ... interested parties will have the opportunity to listen to,the ...
... therapies drugs developed to attack specific molecules in ... work well by themselves, increasingly researchers are finding that ... conventional therapies. , Reported today at the AACR-NCI-EORTC ... applications of new and existing drugs are offering new ...
... Pocket Expenses ... for Medical Foods, NOVATO, ... today that it has,provided a $250,000 grant to the National Organization ... patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds from this,new ...
... NutraCea (OTC Bulletin,Board: NTRZ), a health science company ... nutrient research and technology whose products include,food supplements ... and animals announced today that it has retained ... and an expanded,communications program among the investment community. ...
Cached Medicine News:Health News:Obesity Can Hurt Kids' Hearts 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3
ELISA kit for detection of the cardiac marker Myoglobin. Kit features interchangeable reagents, E-Z Process performed at room temp, and results in less than 1 hour!...
... intended for the quantitative determination of prolactin ... in the diagnosis and treatment of disorders ... BioCheck Prolactin Quantitative Test is based on ... immunosorbent assay. The assay system utilized sheep ...
... assay is an immunometric ('sandwich') ... of Prolactin in human serum ... sample is bound by 2 ... epitopes. One antibody is attached ...
... ELISA Kit is enzyme immunoassay kit ... Prolactin (PRL) concentration in serum. Enzyme ... determination of many protein hormones in ... sensitive, reproducible, rapid and specific assay. ...
Medicine Products: